ECLIPSE: Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

REVIEW UroToday

The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein

The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise in Advanced Prostate Cancer Treatment - Emmanuel Antonarakis

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Metastasis From Malignant Tumor of Prostate
Study ID: NCT05204927

Conference Coverage

Conference Highlights Written by Physician-Scientist